New Delhi, Sept. 30 -- The Central Drugs Standard Control Organisation (CDSCO) has approved Danish drugmaker Novo Nordisk's once-a-week injection for patients suffering from Type 2 diabetes.

In a statement provided to ANI, Novo Nordisk has stated that Ozempic is intended for individuals with Type 2 diabetes and will be available only upon a doctor's prescription.

"Ozempic is meant for people with type 2 diabetes and will be available upon a prescription from a doctor," it said.

"There will be an approved Prescribing Information with the product. It has to be used as per the approved Prescribing Information," said Senior Official.

"Semaglutide Injection (Ozempic@) is indicated for the treatment of Adults with Insufficiently Controlled ...